Clinical Trial Detail

NCT ID NCT02317874
Title Testing the Addition of the Anti-Cancer Drug Talazoparib to the Combination of Carboplatin and Paclitaxel for the Treatment of Advanced Cancer
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

Advanced Solid Tumor

Therapies

Carboplatin + Paclitaxel + Talazoparib

Age Groups: senior adult

No variant requirements are available.